Hollingshead James

About Hollingshead James

James “Jim” Hollingshead is an American corporate executive with a background in medical technology and connected-health businesses. His most notable and most recent leadership role was as President and Chief Executive Officer of Insulet Corporation, a position effective June 1, 2022. Prior to joining Insulet, he spent roughly twelve years at ResMed, where he held several senior leadership roles across strategy, regional operations, and business unit leadership. At ResMed, he first led the strategy and business development function, then served as president of the Americas region, and later became president of the Sleep and Respiratory Care business. ([contracts.justia.com](https://contracts.justia.com/companies/insulet-corp-2296/contract/238670/?utm_source=openai)) At ResMed, Hollingshead was part of the leadership team behind the company’s shift toward a global digital health platform. Public company communications noted that he helped shape the strategy to embed communications capabilities into devices, supporting the broader transformation into a connected health company. He was also credited with helping build a strong leadership bench and preparing the business for continued growth. Taken together, these references point to a background in strategy execution, commercial expansion, and product-platform leadership, especially in connected devices and respiratory care. ([investor.resmed.com](https://investor.resmed.com/news-events/press-releases/detail/47/resmed-announces-leadership-change?utm_source=openai)) His move to Insulet placed him at the helm of a leading diabetes technology company known for its insulin delivery systems. Publicly available sources indicate that he served as CEO from 2022 until 2024, after which he stepped down from the top executive role. Open-source materials reviewed here do not fully detail every major decision he made at Insulet, so it is best to describe his tenure in general terms: he led the company during a period of transition and strategic execution rather than attributing specific actions without stronger sourcing. ([contracts.justia.com](https://contracts.justia.com/companies/insulet-corp-2296/contract/238670/?utm_source=openai)) Overall, James Hollingshead’s career profile reflects senior leadership experience at U.S.-listed healthcare companies. He is best characterized as an executive with expertise in corporate strategy, regional business leadership, and operating growth platforms in regulated medical-device markets. For SEO and corporate-bio purposes, he can be positioned as an experienced MedTech leader with cross-functional leadership experience spanning strategy, commercial operations, and business transformation. ([investor.resmed.com](https://investor.resmed.com/news-events/press-releases/detail/47/resmed-announces-leadership-change?utm_source=openai))